Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
Identifieur interne : 000281 ( PubMed/Curation ); précédent : 000280; suivant : 000282Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
Auteurs : Xuemei Huang [États-Unis] ; Alvaro Alonso ; Xuguang Guo ; David M. Umbach ; Maya L. Lichtenstein ; Christie M. Ballantyne ; Richard B. Mailman ; Thomas H. Mosley ; Honglei ChenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987-89) and at three triennial visits thereafter (visits 2-4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total-cholesterol levels decreased, particularly among statin users. Fifty-six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11-5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30-1.04) for the second and 0.43 (0.22-0.87) for the third tertile (P(trend) = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD.
DOI: 10.1002/mds.26152
PubMed: 25639598
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000281
Links to Exploration step
pubmed:25639598Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.</title><author><name sortKey="Huang, Xuemei" sort="Huang, Xuemei" uniqKey="Huang X" first="Xuemei" last="Huang">Xuemei Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Alonso, Alvaro" sort="Alonso, Alvaro" uniqKey="Alonso A" first="Alvaro" last="Alonso">Alvaro Alonso</name></author><author><name sortKey="Guo, Xuguang" sort="Guo, Xuguang" uniqKey="Guo X" first="Xuguang" last="Guo">Xuguang Guo</name></author><author><name sortKey="Umbach, David M" sort="Umbach, David M" uniqKey="Umbach D" first="David M" last="Umbach">David M. Umbach</name></author><author><name sortKey="Lichtenstein, Maya L" sort="Lichtenstein, Maya L" uniqKey="Lichtenstein M" first="Maya L" last="Lichtenstein">Maya L. Lichtenstein</name></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name></author><author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B" last="Mailman">Richard B. Mailman</name></author><author><name sortKey="Mosley, Thomas H" sort="Mosley, Thomas H" uniqKey="Mosley T" first="Thomas H" last="Mosley">Thomas H. Mosley</name></author><author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25639598</idno><idno type="pmid">25639598</idno><idno type="doi">10.1002/mds.26152</idno><idno type="wicri:Area/PubMed/Corpus">000281</idno><idno type="wicri:Area/PubMed/Curation">000281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.</title><author><name sortKey="Huang, Xuemei" sort="Huang, Xuemei" uniqKey="Huang X" first="Xuemei" last="Huang">Xuemei Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Alonso, Alvaro" sort="Alonso, Alvaro" uniqKey="Alonso A" first="Alvaro" last="Alonso">Alvaro Alonso</name></author><author><name sortKey="Guo, Xuguang" sort="Guo, Xuguang" uniqKey="Guo X" first="Xuguang" last="Guo">Xuguang Guo</name></author><author><name sortKey="Umbach, David M" sort="Umbach, David M" uniqKey="Umbach D" first="David M" last="Umbach">David M. Umbach</name></author><author><name sortKey="Lichtenstein, Maya L" sort="Lichtenstein, Maya L" uniqKey="Lichtenstein M" first="Maya L" last="Lichtenstein">Maya L. Lichtenstein</name></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name></author><author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B" last="Mailman">Richard B. Mailman</name></author><author><name sortKey="Mosley, Thomas H" sort="Mosley, Thomas H" uniqKey="Mosley T" first="Thomas H" last="Mosley">Thomas H. Mosley</name></author><author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987-89) and at three triennial visits thereafter (visits 2-4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total-cholesterol levels decreased, particularly among statin users. Fifty-six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11-5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30-1.04) for the second and 0.43 (0.22-0.87) for the third tertile (P(trend) = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="In-Process"><PMID Version="1">25639598</PMID><DateCreated><Year>2015</Year><Month>04</Month><Day>07</Day></DateCreated><DateRevised><Year>2015</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.</ArticleTitle><Pagination><MedlinePgn>552-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26152</ELocationID><Abstract><AbstractText>Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987-89) and at three triennial visits thereafter (visits 2-4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total-cholesterol levels decreased, particularly among statin users. Fifty-six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11-5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30-1.04) for the second and 0.43 (0.22-0.87) for the third tertile (P(trend) = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xuguang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Umbach</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>Maya L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Ballantyne</LastName><ForeName>Christie M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Mailman</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Honglei</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201100005C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100006C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100006C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100010C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100010C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100012C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100012C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG021491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG21491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES019672</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES019672</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060722</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060722</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS082151</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS082151</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 ES101986-02</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01-ES-101986</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Am J Manag Care. 2013 Aug;19(8):626-32</RefSource><PMID Version="1">24304212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2014 Feb 5;311(5):463-4</RefSource><PMID Version="1">24296612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Apr 10;370(15):1422-31</RefSource><PMID Version="1">24645848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Jul 30;81(5):406-7</RefSource><PMID Version="1">23884043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Jul 30;81(5):410-6</RefSource><PMID Version="1">23884037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2003 Aug;60(8):1059-64</RefSource><PMID Version="1">12925360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bioenerg Biomembr. 2004 Aug;36(4):381-6</RefSource><PMID Version="1">15377876</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 1989 Apr;129(4):687-702</RefSource><PMID Version="1">2646917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb. 1994 Jul;14(7):1098-104</RefSource><PMID Version="1">8018665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 1998 Jul;139(1):189-95</RefSource><PMID Version="1">9699907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 1999 Jan 25;443(2):163-6</RefSource><PMID Version="1">9989597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stroke. 2006 May;37(5):1184-8</RefSource><PMID Version="1">16574924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2006 Nov 15;164(10):998-1002</RefSource><PMID Version="1">16905642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2006 Dec 1;164(11):1075-84</RefSource><PMID Version="1">16982672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Feb 15;22(3):377-81</RefSource><PMID Version="1">17177184</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2007;5:20</RefSource><PMID Version="1">17640385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1418-22</RefSource><PMID Version="1">18184918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2008;31(5):399-407</RefSource><PMID Version="1">18422380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2008 Jun;105(5):1656-67</RefSource><PMID Version="1">18248604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 May 20;70(21):1972-9</RefSource><PMID Version="1">18401018</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 May 15;23(7):1013-8</RefSource><PMID Version="1">18381649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Neurosci. 2008 Nov;15(11):1272-3</RefSource><PMID Version="1">18823780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Cardiovasc Drugs. 2008;8(6):373-418</RefSource><PMID Version="1">19159124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2010 Feb;221(2):267-74</RefSource><PMID Version="1">19944097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2010 Jun 15;293(1-2):82-6</RefSource><PMID Version="1">20347450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2010;340:c2197</RefSource><PMID Version="1">20488911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Jul 15;25(9):1210-6</RefSource><PMID Version="1">20629142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Environ Health Perspect. 2011 Jun;119(6):866-72</RefSource><PMID Version="1">21269927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(6):e20945</RefSource><PMID Version="1">21731633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Lipid Res. 2011 Oct;50(4):357-71</RefSource><PMID Version="1">21741992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2012 Mar;69(3):380-4</RefSource><PMID Version="1">22410446</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">NIHMS651931 [Available on 04/01/16]</OtherID><OtherID Source="NLM">PMC4390443 [Available on 04/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">statin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25639598</ArticleId><ArticleId IdType="doi">10.1002/mds.26152</ArticleId><ArticleId IdType="pmc">PMC4390443</ArticleId><ArticleId IdType="mid">NIHMS651931</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25639598
|texte= Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25639598" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |